|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our analysis indicated neither folate intake nor MTHFR C677T polymorphism is related to altered susceptibility of ovarian cancer.
|
24129496 |
2013 |
|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The C677T polymorphism of the MTHFR gene is associated with the susceptibility of ovarian cancer in Asian population, suggesting that TT genotype may serve as a risk factor of ovarian cancer among Asian but not Caucasians.
|
24720627 |
2014 |
|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
MTHFR C677T polymorphism and ovarian cancer risk: a meta-analysis.
|
23098496 |
2012 |
|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Overall, we observed no association between either SNP and ovarian cancer risk (pooled C677T p(trend)=0.59 and A1298C p(trend)=0.58).
|
20817226 |
2010 |
|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In conclusion, the results of this meta-analysis indicate that the MTHFR C677T and A1298C polymorphisms are not associated with ovarian cancer risk, especially in Caucasians.
|
22810649 |
2012 |
|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This meta-analysis supports an association between MTHFR C677T</span> polymorphism and ovarian cancer risk, and there might be a race-specific effect in this association.
|
23329275 |
2013 |
|
rs1217691063
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In conclusion, we observed that the MTHFR C677T polymorphism is associated with the susceptibility and survival of ovarian cancer in Chinese population.
|
22524826 |
2012 |
|
rs3218536
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The XRCC2 R188H polymorphism was associated with a modest reduction in EOC risk: OR for heterozygotes was 0.8 (95% confidence interval [CI] = 0.7-1.0) and for rare homozygotes 0.3 (0.1-0.9).
|
15924337 |
2005 |
|
rs3218536
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The aim of the present study was to evaluate the role of SNPs in three genes, XRCC2 (R188H), ERCC2 (K751Q) and CDKN1B (V109G) which are with moderate risk for ovarian cancer susceptibility in Egyptian women.
|
23277402 |
2013 |
|
rs3218536
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The current meta-analysis indicated that the Arg188His polymorphism in the XRCC2 gene might be a risk factor for ovarian cancer.
|
24414483 |
2014 |
|
rs3218536
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Overall, a significant association was found between the Arg188His polymorphism and ovarian cancer risk when all studies were pooled into the meta-analysis (Arg/Arg vs His/His: OR = 1.85, 95%CI = 1.15-3.00; Arg/Arg vs Arg/His: OR = 1.17, 95%CI = 1.03-1.32; dominant model: OR = 0.84, 95%CI = 0.74-0.95; recessive model: OR = 1.69, 95%CI = 1.05-2.70).
|
26400309 |
2015 |
|
rs3218536
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Interestingly, XRCC2 G>A (rs3218536) polymorphism might reduce the risk of ovarian cancer.
|
24599673 |
2014 |
|
rs3218536
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The obtained results indicate that XRCC2 Arg188His and XRCC3 Thr241Met polymorphisms may be positively associated with the incidence of ovarian carcinoma in the population of Polish women.
|
26801223 |
2016 |
|
rs3218536
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In conclusion, this meta-analysis indicates that XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms may not be associated with the risk of OC.
|
27863412 |
2016 |
|
rs1695
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Several studies have examined whether GST polymorphisms (GSTM1 null/present genotype, GSTT1 null/present genotype, and GSTP1 Ile105Val) represent risk factors for ovarian cancer, as they all may denote reduced enzyme activity.
|
20966642 |
2010 |
|
rs1695
|
|
|
0.060 |
GeneticVariation |
BEFREE |
This study aimed to evaluate whether GSTM1 and GSTT1 (presents or nulls), GSTP1 c.313A>G and NQO2 c.-102A>C polymorphisms, involved in xenobiotic detoxification pathways, alter outcomes of epithelial ovarian cancer (EOC) patients.
|
27586145 |
2016 |
|
rs1695
|
|
|
0.060 |
GeneticVariation |
BEFREE |
<i>GSTP1</i> rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes.
|
30038720 |
2018 |
|
rs1695
|
|
|
0.060 |
GeneticVariation |
BEFREE |
We tested in this study whether the GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms alter the risk of EOC.
|
22960333 |
2012 |
|
rs1695
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Large epidemiological studies with the combination of GSTM1 null, GSTT1 null and GSTP1 Ile105Val polymorphisms and more specific histological subtypes of OC are needed to prove our findings.
|
25124586 |
2014 |
|
rs1695
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Genetic polymorphisms such as ERCC1 8092C>A, ABCB1 2677G>T/A, GSTP1 I105V and GSTT1 polymorphisms may affect drug response, toxicity and survival in patient with EOC who received taxane- and platinum-based chemotherapy after surgery.
|
19203783 |
2009 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
One recurrent somatic mutation, p.V600E, is frequently found in several tumor types, such as melanoma, papillary thyroid carcinoma, colon cancer, and ovarian cancer.
|
20735442 |
2011 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Germ line and somatic mutations of BRAF V599E in ovarian carcinoma.
|
17309670 |
2007 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The presence of the BRAF V600E mutation in SB/LGS ovarian cancer was associated with early stage disease and improved prognosis.
|
22930283 |
2013 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
A patient with V600E BRAF-mutant melanoma and another with platinum-refractory epithelial ovarian cancer exhibiting PTEN loss and PIK3CA amplification demonstrated partial response by RECIST and GCIG-CA125 criteria, respectively.
|
25370471 |
2015 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
|
26490654 |
2015 |